Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis

BackgroundAspirin use has been suggested to reduce the incidence of ovarian cancer (OC) in women. However, previous studies regarding the association between aspirin use and mortality in women with OC showed inconsistent results. We aimed to evaluate the association between aspirin use and mortality...

Full description

Bibliographic Details
Main Authors: Xiaxia Man, Baogang Wang, Yuying Tan, Xiaolin Yang, Songling Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.575831/full
id doaj-348a5ea361f14e5db6be5567b6cac7bd
record_format Article
spelling doaj-348a5ea361f14e5db6be5567b6cac7bd2021-02-01T06:20:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-02-011010.3389/fonc.2020.575831575831Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-AnalysisXiaxia Man0Baogang Wang1Yuying Tan2Xiaolin Yang3Songling Zhang4Department of Oncological Gynecology, First Hospital, Jilin University, Changchun, ChinaDepartment of Cardiac Surgery, First Hospital, Jilin University, Changchun, ChinaDepartment of Echocardiography, First Hospital, Jilin University, Changchun, ChinaDepartment of Geriatrics, First Hospital, Jilin University, Changchun, ChinaDepartment of Oncological Gynecology, First Hospital, Jilin University, Changchun, ChinaBackgroundAspirin use has been suggested to reduce the incidence of ovarian cancer (OC) in women. However, previous studies regarding the association between aspirin use and mortality in women with OC showed inconsistent results. We aimed to evaluate the association between aspirin use and mortality in women with OC in a meta-analysis.MethodsRelevant cohort studies were obtained via search of PubMed, Cochrane’s Library, and Embase databases from inception to May 3, 2020. A random-effect model, which incorporates the potential heterogeneity among the included studies, was used to pool the results. Predefined stratified analyses were applied to evaluate the potential study characteristics on the outcome, including the timing of aspirin use, dose of aspirin, age of the women, and the clinical stages of the cancer. Sensitivity analysis by omitting one study at a time was used to assess the stability of the results.ResultsSix cohort studies including 17,981 women with OC were included. Pooled results showed that aspirin use had no statistically significant association with mortality in these patients (adjusted risk ratio [RR]: 0.85, 95% confidence interval [CI]: 0.70 to 1.02, p = 0.08; I2 = 69%). The results were similar for OC-specific mortality (RR: 0.85, 95% CI: 0.57 to 1.26, p = 0.41) and all-cause mortality (RR: 0.78, 95% CI: 0.55 to 1.11, p = 0.17). Stratified analyses suggested that aspirin use had no statistically significant association with mortality risk in OC regardless the timing of aspirin use, dose of aspirin, age of the women, or the clinical stages of the cancer. Funnel plots suggested potential risk of publication bias (p all > 0.05). However, further “trim-and-fill” analysis incorporating hypothesized unpolished studies to achieve symmetrical funnel plots showed similar results of the meta-analysis (RR: 0.91, 95% CI: 0.74 to 1.13, p = 0.39).ConclusionsCurrent evidence from observational studies indicated that aspirin use had no statistically significant association with mortality in women with OC.https://www.frontiersin.org/articles/10.3389/fonc.2020.575831/fullaspirinovarian carcinomamortalitycohort studiesmeta-analysis
collection DOAJ
language English
format Article
sources DOAJ
author Xiaxia Man
Baogang Wang
Yuying Tan
Xiaolin Yang
Songling Zhang
spellingShingle Xiaxia Man
Baogang Wang
Yuying Tan
Xiaolin Yang
Songling Zhang
Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis
Frontiers in Oncology
aspirin
ovarian carcinoma
mortality
cohort studies
meta-analysis
author_facet Xiaxia Man
Baogang Wang
Yuying Tan
Xiaolin Yang
Songling Zhang
author_sort Xiaxia Man
title Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis
title_short Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis
title_full Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis
title_fullStr Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis
title_full_unstemmed Aspirin Use and Mortality in Women With Ovarian Cancer: A Meta-Analysis
title_sort aspirin use and mortality in women with ovarian cancer: a meta-analysis
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-02-01
description BackgroundAspirin use has been suggested to reduce the incidence of ovarian cancer (OC) in women. However, previous studies regarding the association between aspirin use and mortality in women with OC showed inconsistent results. We aimed to evaluate the association between aspirin use and mortality in women with OC in a meta-analysis.MethodsRelevant cohort studies were obtained via search of PubMed, Cochrane’s Library, and Embase databases from inception to May 3, 2020. A random-effect model, which incorporates the potential heterogeneity among the included studies, was used to pool the results. Predefined stratified analyses were applied to evaluate the potential study characteristics on the outcome, including the timing of aspirin use, dose of aspirin, age of the women, and the clinical stages of the cancer. Sensitivity analysis by omitting one study at a time was used to assess the stability of the results.ResultsSix cohort studies including 17,981 women with OC were included. Pooled results showed that aspirin use had no statistically significant association with mortality in these patients (adjusted risk ratio [RR]: 0.85, 95% confidence interval [CI]: 0.70 to 1.02, p = 0.08; I2 = 69%). The results were similar for OC-specific mortality (RR: 0.85, 95% CI: 0.57 to 1.26, p = 0.41) and all-cause mortality (RR: 0.78, 95% CI: 0.55 to 1.11, p = 0.17). Stratified analyses suggested that aspirin use had no statistically significant association with mortality risk in OC regardless the timing of aspirin use, dose of aspirin, age of the women, or the clinical stages of the cancer. Funnel plots suggested potential risk of publication bias (p all > 0.05). However, further “trim-and-fill” analysis incorporating hypothesized unpolished studies to achieve symmetrical funnel plots showed similar results of the meta-analysis (RR: 0.91, 95% CI: 0.74 to 1.13, p = 0.39).ConclusionsCurrent evidence from observational studies indicated that aspirin use had no statistically significant association with mortality in women with OC.
topic aspirin
ovarian carcinoma
mortality
cohort studies
meta-analysis
url https://www.frontiersin.org/articles/10.3389/fonc.2020.575831/full
work_keys_str_mv AT xiaxiaman aspirinuseandmortalityinwomenwithovariancancerametaanalysis
AT baogangwang aspirinuseandmortalityinwomenwithovariancancerametaanalysis
AT yuyingtan aspirinuseandmortalityinwomenwithovariancancerametaanalysis
AT xiaolinyang aspirinuseandmortalityinwomenwithovariancancerametaanalysis
AT songlingzhang aspirinuseandmortalityinwomenwithovariancancerametaanalysis
_version_ 1724315737514835968